GlassScriptPhysician profile
Jeffrey Lee Bitterling
NPI 1154469625
$2,871.67
in general payments reported to CMS, 2019-2025
24 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $210 · 2021: $495 · 2022: $609 · 2023: $498 · 2024: $499 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $608.46 | 2021-2025 | Azstarys |
| Glaxosmithkline, LLC. | $370.18 | 2019-2024 | Bexsero, Rotarix, Pediarix |
| Tris Pharma INC | $272.16 | 2020-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $253.61 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $239.94 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $186.91 | 2019-2025 | |
| Cranial Technologies, INC | $165.25 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $124.99 | 2020-2024 | Gardasil 9, Vaxneuvance, Proquad |
| Pfizer INC. | $90.85 | 2022-2025 | |
| Adlon Therapeutics L.P. | $75.68 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $74.23 | 2021-2023 | |
| Pharming Healthcare, INC. | $66.45 | 2023-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $65.65 | 2024 | |
| Sobi, INC | $57.93 | 2021-2022 | |
| Shire North American Group INC | $53.66 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $34.72 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $25.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $21.23 | 2023 | Flumist Quadrivalent |
| Ironwood Pharmaceuticals, INC | $16.75 | 2024 | |
| Neurelis, INC. | $15.72 | 2023 | Valtoco |
| Arbor Pharmaceuticals, INC. | $14.90 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.47 | 2023 | Ycanth |
| Genentech USA, INC. | $11.59 | 2021 | |
| Abbvie INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bitterling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.